| Value | ₹0.01 Cr |
|---|
NSE filing, NSE: INVICTA. Summary written from the filing by ALFA Finder's alert engine.
Invicta Diagnostic Ltd: key numbers
- Share price
- ₹65.00
- Market cap
- ₹81.72 Cr
- Revenue (annual)
- ₹32.35 Cr
- Net profit (annual)
- ₹4.91 Cr
- P/E (TTM)
- 16.7×Sector 52.0×
- Promoter holding
- 66.70%
- FII holding
- 1.54%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Invicta Diagnostic Ltd
All →Invicta Diagnostic Management Change
Invicta Diagnostic Limited reported changes to its leadership and audit team, including a director's re-appointment, a designation change, and a new secretarial auditor.
Invicta Diagnostic Annual General Meeting
Invicta Diagnostic Limited conducted its 3rd Annual General Meeting on September 19, 2026. The proceedings detailed company operations and future financial targets.
Invicta Diagnostic Board Meeting Outcome
Board approved business outlook and forward-looking guidance for the 3rd AGM on 19 September 2026. Company targets consolidated revenue of ₹45–50 crore with ~25% EBITDA margin.
Invicta Diagnostic Capacity Expansion
Invicta's subsidiaries commenced operations at two diagnostic centres in Shegaon and Pune. Investment is Rs. 70 lakhs for CT scan and pathology services.
- diagnostic service centres
- 2 centres
Invicta Diagnostic Annual General Meeting
Invicta Diagnostic approved the notice for its 3rd Annual General Meeting scheduled for 19th September 2026, alongside adoption of financial reports and director appointments.
Invicta Diagnostic Management Change
Invicta Diagnostic Limited announced the resignations of Executive Director Rohit Prakash Srivastava and Manager Konica Rohit Srivastava. Additionally, Director Sanket Vinod Jain was redesignated as Executive Director.
Other merger & restructuring announcements
All →Quint Digital Merger & Restructuring
Quint Digital's board approved a Rule 10b5-1 trading plan and the incorporation of a wholly owned overseas subsidiary. No investment amount was disclosed.
Hexaware Technologies Merger & Restructuring
Hexaware Technologies approved a slump sale of its step-down subsidiary Tech SMC Square India to Tech SMC Squared (GCC) India, a related-party deal. Consideration is cash, yet to be set by a registered valuer.
- Execution
- Expected completion by 30 June 2027; agreement date stated as 1 December 2026
Emkay Global Financial Services Merger & Restructuring Worth ₹2.75 Cr
Emkay Global agreed to sell its Wealth Management Business to a step-down subsidiary, Emkay Wealth Advisory, for Rs. 2.75 Crore cash. Completion is expected by 26 January 2027.
- Value
- ₹2.75 Cr
- Execution
- Completion expected by 26 January 2027
TVS Holdings Merger & Restructuring
TVS Holdings forwarded TVS Motor's board outcome of October 28, 2026 approving acquisition of Harita ARC and a composite scheme of amalgamation and demerger. The scheme is subject to stock exchange, SEBI, NCLT and shareholder approvals.
Emkay Global Financial Services Merger & Restructuring Worth ₹30 Cr
Emkay Global approved transferring two subsidiaries to new subsidiary ECPL and slump-selling its wealth business. Up to Rs.30 Crore rights investment in ECPL was also approved.
- Value
- ₹30.00 Cr
- Execution
- Divestment completion expected within 90 days of SPA execution, subject to regulatory approvals
Fortis Healthcare Merger & Restructuring Worth ₹277 Cr
Fortis subsidiary International Hospital acquired Suguna Ramaiah Hospitals' business, operations, land and building for Rs 277 Crore cash. The deal was consummated today, strengthening Bengaluru presence.
- Value
- ₹277.0 Cr